Compare MHH & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | CRDF |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 67.1M |
| IPO Year | 2008 | 2012 |
| Metric | MHH | CRDF |
|---|---|---|
| Price | $6.34 | $0.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | ★ $12.75 | $6.28 |
| AVG Volume (30 Days) | 7.0K | ★ 346.5K |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,371,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.94 | $5.62 |
| P/E Ratio | $627.00 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $5.50 | $0.71 |
| 52 Week High | $8.37 | $3.31 |
| Indicator | MHH | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 30.76 |
| Support Level | $6.24 | N/A |
| Resistance Level | $6.84 | $1.13 |
| Average True Range (ATR) | 0.32 | 0.06 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 10.35 | 5.60 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.